Financial terms were not disclosed, although Nordion will leave an estimated US$18m in the company.
Best Medical has acquired all of MDS Nordion, with the exception of the TheraSphere business, which develops liver cancer therapeutics.
The firm bought another Nordion company, Ottawa-based Theratronics, four years ago.
Nordion made a decision in the 2010 financial year to restructure or exit this business, stating that it wanted to reduce complexity, manage costs and focus on growing areas of the business.
The 55 employees at MDS Nordion will transfer to Best Medical, which will also acquire the Belgian production facilities.
Nordion expects the transaction to be completed in the next few months.
Nordion sells Belgian operation
Best Medical to buy MDS Nordion, terms not revealed
You may also like
Finance
HitGen secures Gates Foundation funding to advance drug discovery for tuberculosis, malaria and contraception
Read moreHitGen will use its DNA-encoded library platform to identify new drug leads for TB, malaria and non-hormonal contraception. The new Gates Foundation agreement expands on earlier collaboration to accelerate treatments for underserved diseases
Trending Articles
You may also like
Finance
HitGen secures Gates Foundation funding to advance drug discovery for tuberculosis, malaria and contraception
HitGen will use its DNA-encoded library platform to identify new drug leads for TB, malaria and non-hormonal contraception. The new Gates Foundation agreement expands on earlier collaboration to accelerate treatments for underserved diseases
Finance
hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline
hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group
Finance
Sofinnova Partners closes €650m ($750m) Capital XI fund to boost early-stage biotech investment across Europe and the US
Sofinnova Partners has closed its flagship Capital XI fund at €650m, surpassing its target. The Paris-based firm will use the fund to advance early-stage biotech and medtech companies in Europe and North America